Eli Lilly deploys weight-loss cash on ‘App Store’ for scientists
Summary
Eli Lilly is channeling its weight-loss profits into AI-enabled drug discovery and a biotech collaboration hub. The company has built a dedicated data center, partnered with around 100 smaller biotechs, and compared the effort to an App Store for scientists. It has also signed numerous third-party AI licensing deals and made a major investment in Insilico Medicine. The move reflects Lilly’s push to diversify ahead of future patent expirations while expanding its R&D capabilities.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected